Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Key Highlights
- ➤Recursion (RXRX) priced 61.54 million shares at $3.25 each
- ➤Offering expected to generate approximately $200 million in gross proceeds
- ➤Offering is expected to close on or about October 16, 2026
- ➤Healthcare and institutional investors participated in the financing
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per share. All of the shares are to be sold by Recursion. Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on or about October 16, 2026, subject to satisfaction of customary closing conditions.
Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C. are acting as joint bookrunning managers for the offering. Needham & Company, LLC is acting as lead manager for the offering.
Get started
Create a free account to read the full story.